Table 1. Demographics and clinical characteristics of the three groups.
| Characteristic | Controls (n=14) | Eosinophilic COPD (n=42) | Non-eosinophilic COPD (n=20) | P |
|---|---|---|---|---|
| Age, years | 70.07±7.21 | 66.25±7.34 | 66.03±8.95 | 0.205 |
| Gender, M/F | 11/3 | 41/1 | 20/0 | 0.010 |
| BMI (kg/m2) | 23.84±5.36 | 21.77±3.77 | 21.48±3.98 | 0.146 |
| Smoking, n (never/ex/current) | 6/7/1 | 3/29/10 | 2/14/4 | 0.019 |
| Pre-BD FEV1 (L) | 2.34±0.49 | 1.21±0.59a | 1.37±0.55a | <0.001 |
| Pre-BD FEV1%pred (%) | 95.62±11.25 | 46.58±20.43a | 52.62±21.77a | <0.001 |
| Pre-BD FVC (L) | 2.88±0.59 | 2.50±0.79 | 2.72±0.67 | 0.122 |
| Pre-BD FEV1/FVC | 0.81±0.04 | 0.47±0.12a | 0.50±0.14a | <0.001 |
| Post-BD FEV1 (L) | NA | 1.36±0.62 | 1.52±0.59 | 0.185 |
| Post-BD FEV1%pred (%) | NA | 52.25±21.46 | 58.79±24.70 | 0.156 |
| Post-BD FVC (L) | NA | 2.74±0.75 | 2.84±0.71 | 0.466 |
| Post-BD FEV1/FVC | NA | 0.48±0.12 | 0.56±0.31 | 0.165 |
| CAT score | NA | 11 (6–17) | 10 (5–14) | 0.334 |
| mMRC | NA | 2(1–2) | 1 (1–2) | 0.449 |
| Exacerbations in the previous year | NA | 1 (0–1) | 0 (0–1) | 0.387 |
| Medications | ||||
| LAMA | NA | 17 (40.5%) | 10 (50%) | 0.480 |
| LABA | NA | 29 (64%) | 10 (50%) | 0.147 |
| ICS | NA | 29 (64%) | 11 (55%) | 0.280 |
| Oral aminophylline | NA | 18 (42.9%) | 7 (35%) | 0.555 |
| Oral corticosteroid | NA | 0 | 0 | – |
Eosinophilic COPD is defined as ≥3% sputum eosinophils, and non-eosinophilic COPD is defined as <3% sputum eosinophils. Data are presented as n (%), mean ± SD or median (interquartile range), unless otherwise stated. Pre-BD, pre-bronchodilator; Post-BD, post-bronchodilator; BMI, body mass index; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; FEV1%pred, forced expiratory volume in 1 s in the percentage of predicted; FVCpred%, forced vital capacity in the percentage of predicted; CAT, chronic obstructive pulmonary disease (COPD) assessment test; mMRC, Modified Medical Research Council Dyspnea Scale. aP<0.05 vs. control group.